US 11,911,388 B2
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
Eva Ulrike Graefe-Mody, Ingelheim am Rhein (DE); Thomas Klein, Radolfzell (DE); Michael Mark, Biberach an der Riss (DE); and Hans-Juergen Woerle, Munich (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Feb. 11, 2021, as Appl. No. 17/173,607.
Application 17/173,607 is a continuation of application No. 16/196,592, filed on Nov. 20, 2018, abandoned.
Application 16/196,592 is a continuation of application No. 15/698,696, filed on Sep. 8, 2017, abandoned.
Application 15/698,696 is a continuation of application No. 14/939,169, filed on Nov. 12, 2015, abandoned.
Application 14/939,169 is a continuation of application No. 13/124,196, abandoned, previously published as PCT/EP2009/063511, filed on Oct. 15, 2009.
Claims priority of provisional application 61/105,919, filed on Oct. 16, 2008.
Claims priority of application No. 08166829 (EP), filed on Oct. 16, 2008; and application No. 09167304 (EP), filed on Aug. 5, 2009.
Prior Publication US 2021/0161903 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/155 (2006.01); A61K 31/522 (2006.01); A61K 38/28 (2006.01); A61K 9/00 (2006.01); A61P 3/10 (2006.01); A61K 31/4439 (2006.01); A61K 31/64 (2006.01)
CPC A61K 31/522 (2013.01) [A61K 9/0053 (2013.01); A61K 31/155 (2013.01); A61K 31/4439 (2013.01); A61K 31/64 (2013.01); A61K 38/28 (2013.01); A61P 3/10 (2018.01)] 11 Claims
 
1. A method for treating metabolic diseases in type 2 diabetes patients with renal impairment and with insufficient glycemic control despite either metformin monotherapy or therapy with metformin in combination with an insulin or an insulin analogue, the method comprising administering a DPP-4 inhibitor which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a pharmaceutically acceptable salt thereof, in an oral daily amount of 5 mg, wherein said 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a pharmaceutically acceptable salt thereof, is used in combination with either metformin monotherapy or metformin in combination with an insulin or an insulin analogue.